It is interesting that, although our MTHFD inhibitors also enzymatically inhibit MTHFD2L and the DC domain of MTHFD1, the cancer-selective properties observed following MTHFD2 siRNA depletion remain the same using the MTHFD2 inhibitors, which could potentially be due to the relatively low expression levels of MTHFD1 compared with MTHFD2 in cancer cells. This evidence concerns the gene MTHFD2L and cancer.